poisar

Stocks · News reference

Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL

Jun 9, 2026, 8:32 PMBenzinga Newsdesk

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CLLS
Source
benzinga
Observed
Jun 9, 2026, 8:32 PM
Checked
Jun 9, 2026, 8:32 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading